EUVIMEDEUVIMED entdecken
Crossref

Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy

Shuqing Li, Zhihao Hu, Wanyi Pan, Haiyan Wu, Weijie Peng, Yi Wu, Feng Jiang, Xiaopeng Peng iD

Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 3212-3237

DOI: 10.1021/acs.jmedchem.4c02445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 28.01.2025. Verfasst von Shuqing Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Disease, Ministry of Education; Jiangxi Provincal Key Laboratory of …. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Histone Deacetylases, DNA Damage, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Bureau of Science and Technology of Ganzhou Municipality, National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylase 3 (HDAC3) is a well-established target for cancer therapy. Herein, we developed LSQ-28 as a novel HDAC3 inhibitor, which exhibited high HDAC3 inhibitory activity (IC50 = 42 nM, SI > 161) and displayed potent antiproliferative activity against four cancer cells and further demonstrated excellent antimigratory, anti-invasive, and antiwound healing activities. Further studies revealed that LSQ-28 induced a dose-dependent increase in Ac-H3 expression and promoted the degradation of PD-L1. Additionally, LSQ-28 enhanced the DNA damage response induced by PARP inhibitor, as evidenced by regulated expression of PARP1 and γ-H2AX. Notably, LSQ-28 also possessed favorable pharmacokinetic properties with significant oral bioavailability (F = 95.34%). Importantly, the combination of LSQ-28 with the PD-L1 inhibitor NP-19 could enhance antitumor immune response (TGI = 80%). When combined with olaparib, LSQ-28 significantly enhanced the in vivo tumor-suppression activity (TGI = 91%). Collectively, LSQ-28 represents a promising HDAC3 inhibitor for further exploration in cancer therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsHistone DeacetylasesDNA DamageAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorAdministration, OralImmunologic FactorsCell ProliferationBiological AvailabilityDrug DiscoveryStructure-Activity RelationshipNeoplasmsMaleB7-H1 AntigenHistone Deacetylase 3

Substanzen

Histone Deacetylase InhibitorsHistone DeacetylasesAntineoplastic AgentsImmunologic FactorsB7-H1 AntigenHistone Deacetylase 3

Autor:innen und Institutionen

  • Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Disease, Ministry of Education; Jiangxi Provincal Key Laboratory of Tissue Engineering; College of Pharmacy, Gannan Medical University, Ga…

ORCID-Profile: Xiaopeng Peng

Förderung

  • Bureau of Science and Technology of Ganzhou Municipality
  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangxi Province
  • Gannan Medical University
  • Jiangxi Provincial Key Laboratory of Tissue Engineering

Zitieren

APA

Li, S., Hu, Z., Pan, W., Wu, H., Peng, W., Wu, Y., Jiang, F., & Peng, X. (2025). Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy. Journal of Medicinal Chemistry, 68(3), 3212-3237. https://doi.org/10.1021/acs.jmedchem.4c02445

Vancouver

Li S, Hu Z, Pan W, Wu H, Peng W, Wu Y, et al. Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy. Journal of Medicinal Chemistry. 2025;68(3):3212-3237. doi:10.1021/acs.jmedchem.4c02445

BibTeX
@article{Li2025,
  author = {Li, Shuqing and Hu, Zhihao and Pan, Wanyi and Wu, Haiyan and Peng, Weijie and Wu, Yi and Jiang, Feng and Peng, Xiaopeng},
  title = {Discovery of Highly Potent and Orally Bioavailable Histone Deacetylase 3 Inhibitors as Immunomodulators and Enhancers of DNA-Damage Response in Cancer Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {3},
  pages = {3212--3237},
  doi = {10.1021/acs.jmedchem.4c02445}
}
Kostenlos starten →